INDIGO’s assay kits and services can provide valuable information for your cancer research. Whether you are interested in a single-receptor assay or a full-panel study, we can help you obtain the data you need quickly.
Nuclear Receptors for Cancer Research
Nuclear receptors have long been targets in oncology research and the role of dysregulated nuclear receptor mediated signaling pathways in tumorigenesis has been well documented in a variety of cancers. Small molecule drugs that modulate nuclear receptors have proven to be effective therapeutic targets, such as with antagonists of the androgen receptor (AR) in patients with prostate cancer or the estrogen receptor alpha (ERα) in patients with ERα positive breast cancer. Nuclear receptors also play critical roles in the signaling pathways for inflammation and immunity and these pathways have been widely implicated in oncogenesis and may be potent therapeutic avenue for new cancer treatments.
Growth Factor Receptors for Cancer Research
Growth factor receptors are important targets in oncology because mutations that lead to constitutive activation of these signal pathways result in the progression of various types of cancers. Overexpression of receptor tyrosine kinases (RTK), which include the epidermal growth factor receptor (EGFR) family and the vascular endothelial growth factor receptor (VEGFR) family, among others, have been found in many tumors. Mutations in serine/threonine-specific protein kinase receptors such as transforming growth factor-beta (TGFβR) have also been linked to growth of many tumors due to defects in the cellular growth inhibition response to TGFβ. As discovery research continues, growth factors and growth factor signaling pathways remain promising targets in the development of oncologic therapeutics.